173 related articles for article (PubMed ID: 37906351)
1. Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.
Xing B; Zhang X; Gu X; Xiang L; Wang C; Jin Y
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17529-17541. PubMed ID: 37906351
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Mediated Gene Knockout of ARID1A Promotes Primary Progesterone Resistance by Downregulating Progesterone Receptor B in Endometrial Cancer Cells.
Wang H; Tang Z; Li T; Liu M; Li Y; Xing B
Oncol Res; 2019 Sep; 27(9):1051-1060. PubMed ID: 31072420
[TBL] [Abstract][Full Text] [Related]
4. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
5. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
[TBL] [Abstract][Full Text] [Related]
7. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
8. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
9. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
Wilson MR; Reske JJ; Holladay J; Wilber GE; Rhodes M; Koeman J; Adams M; Johnson B; Su RW; Joshi NR; Patterson AL; Shen H; Leach RE; Teixeira JM; Fazleabas AT; Chandler RL
Nat Commun; 2019 Aug; 10(1):3554. PubMed ID: 31391455
[TBL] [Abstract][Full Text] [Related]
10. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of mutated ARID1A inhibited endometrial cancer cell proliferation and stimulated cell apoptosis.
Ye Y; Wei B; Xiaowei X
J BUON; 2018; 23(4):1082-1091. PubMed ID: 30358215
[TBL] [Abstract][Full Text] [Related]
12. The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.
Toumpeki C; Liberis A; Tsirkas I; Tsirka T; Kalagasidou S; Inagamova L; Anthoulaki X; Tsatsaris G; Kontomanolis EN
In Vivo; 2019; 33(3):659-667. PubMed ID: 31028182
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
Tessiri S; Techasen A; Kongpetch S; Namjan A; Loilome W; Chan-On W; Thanan R; Jusakul A
PeerJ; 2022; 10():e12750. PubMed ID: 35070505
[TBL] [Abstract][Full Text] [Related]
14. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
15. ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer.
Sato T; Saito M; Nakajima S; Saito K; Katagata M; Fukai S; Okayama H; Sakamoto W; Saze Z; Momma T; Mimura K; Kono K
Gastric Cancer; 2023 May; 26(3):379-392. PubMed ID: 36811690
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways.
Hu Z; Long T; Ma Y; Zhu J; Gao L; Zhong Y; Wang X; Wang X; Li Z
J Exp Clin Cancer Res; 2020 May; 39(1):76. PubMed ID: 32370786
[TBL] [Abstract][Full Text] [Related]
18. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
19. Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma.
Zhang FK; Ni QZ; Wang K; Cao HJ; Guan DX; Zhang EB; Ma N; Wang YK; Zheng QW; Xu S; Zhu B; Chen TW; Xia J; Qiu XS; Ding XF; Jiang H; Qiu L; Wang X; Chen W; Cheng SQ; Xie D; Li JJ
Cell Mol Gastroenterol Hepatol; 2022; 14(1):101-127. PubMed ID: 35390516
[TBL] [Abstract][Full Text] [Related]
20. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
[Next] [New Search]
